Down-Regulation of CXXC5 De-Represses MYCL1 to Promote Hepatic Stellate Cell Activation
Xiaoyan Wu(Shenzhen University), Xiaolei Shi(Nanjing Drum Tower Hospital), Longcheng Shang(China Pharmaceutical University), Haozhen Ren(Nanjing Drum Tower Hospital), Wei Zhu(Ministry of Education of the People's Republic of China), Jinglin Wang(Guizhou Provincial People's Hospital), Wenhui Dong(Weifang People's Hospital), Ming Kong(Soonchunhyang University Hospital Seoul), Zhengyi Zhu(Nanjing Drum Tower Hospital)
Cited by 27
Related Papers
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
|Annals of the Rheumatic Diseases|2011|412
Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases
|PLoS ONE|2012|196
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
|Annals of the Rheumatic Diseases|2013|168